RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsDecember 15, 2022 - PwC’s partner and pharmaceutical and life sciences deals leader Roel Van den Akker expects deal size to remain in the $5 billion to $15 billion range, as FTC chair Lina Khan promises to crack down on “the biggest mergers and where we see the most market power.” “Good corporate cash remains, there’s fantastic late-stage science out there, still unmet medical need, and we’ve got this portfolio gap that a lot of the companies are sort of struggling with [in the] latter half of the decade,” Van der Akker said.
https://endpts.com/despite-lackluster-2022-pwc-remains-bullish-on-pharma-ma-in-2023/